Richter Pharma AG" as distributor of the veterinary medicinal product "Doxapram-V", which is approved in Germany, has informed its customers that batch 0617569AA is being recalled by the marketing authorization holder "Albrecht GmbH". The reason is a…

The Federal Office for Safety in Health Care was informed by the Hungarian authority that two confirmed human WNV infections occurred in Perkata (Fejèr County) and in Balatonfüred (Veszprèm County).

The Federal Office for Safety in Health Care has been informed by the Italian authority that WNV NAT positive mosquito pools have been identified in the regions of Verona, Padua and Rovigo (Veneto Region). For this reason, ID WNV NAT testing is performed for donors of blood and blood components in these regions.

The BASG has been approved by the competent authority in Great Britain (Medicines & Healthcare products Regulatory Agency - MHRA) informs that the products listed are unlawfully available on the market. were brought. The manufacturer has not provided sufficient evidence that the products comply with the comply with legal requirements.

The marketing authorization holder informed its supplied customers in a letter dated 06.07.2018 that a production-related contamination of the active ingredient was detected. The substance in question is N-nitrosodimethylamine (NDMA). Therefore, a…

In a letter dated July 6, 2018, the marketing authorization holder informed its customers that a production-related contamination of the active ingredient has been detected. Therefore, a precautionary recall of all batches of "Valsartan Sandoz…

No acute danger. Discontinuation of medication not recommended

A batch-related recall of medicines containing valsartan, the active ingredient of which was produced by the Chinese manufacturer Zhejiang Huahai Pharmaceutical, is currently taking place in the European Union. The affected drugs are used to treat…

The marketing authorization holder has informed its supplied customers in a letter dated July 4, 2018, that the active ingredient valsartan may contain a genotoxic impurity with carcinogenic potential.Based on this information from the active…

The marketing authorization holder has informed its supplied customers in a letter dated 04.07.2018 that the active ingredient Valsartan may contain a genotoxic impurity with carcinogenic potential. Based on this information from the active…